Multi-dosage conversion of Shuanghuang Chuanku Pills Veterinary Grade API across tablet, injection, capsule, powder, granule, premix, and solution lines is constrained by the same root parameter: the material behaves as a multicomponent botanical preparation rather than a single crystalline chemical entity. Batch-to-batch variability is therefore managed through high-performance thin-layer chromatography or high-performance liquid chromatography fingerprinting against a qualified reference batch, not through a single assay value. Incoming lots should be tested for total ash, acid-insoluble ash, heavy metals by Ph. Eur. 2.4.8 or USP <231>, residual solvents by VICH GL18, and microbiological load by Ph. Eur. 5.1.4 before any dosage-form work begins. Material below 0.250 mm often exhibits poor flow and high equilibrium moisture; where the supplier certificate of analysis reports loss on drying above 5.0%, the lot must be pre-dried at 50–55°C under vacuum or in a fluid bed with dew point control before tableting or capsule filling. These limits are not pharmacopoeial monographs for the product but are standard manufacturing release gates for botanical veterinary APIs; published data for this specific configuration is limited, and each site should qualify local ranges against three consecutive production batches.

What Limits the Compression Window in Multicomponent Botanical Fractions with Residual Polyphenols?

Compression of the API into immediate-release veterinary tablets is most sensitive to moisture-induced stickiness and capping at the die wall. Direct compression trials should start with a microcrystalline cellulose and lactose monohydrate co-diluent at a total excipient load of 40–60% w/w, croscarmellose sodium or crospovidone at 2.0–4.0% w/w, colloidal silicon dioxide at 0.2–0.5% w/w, and magnesium stearate at 0.5–1.0% w/w. If ejection force on a rotary tablet press exceeds 2.5 kN at a compression force of 8–12 kN, the lubricant level is increased stepwise within this range; above 1.5% w/w magnesium stearate, tensile strength can fall below 1.0 MPa as measured by a standard diametral compression test. For granulation-based routes, a hydroalcoholic binder of povidone K30 at 2.0–5.0% w/w prepared in 50–70% v/v ethanol is sprayed during high-shear mixing at an impeller speed of 150–250 rpm, followed by drying in a fluid bed with inlet air at 55–65°C until loss on drying is 2.0–3.5%. Dried granules are screened through 0.8–1.0 mm and blended with extragranular disintegrant before lubrication. Tablets compressed from qualified granules should exhibit hardness 60–100 N, friability ≤ 1.0% after 100 revolutions per USP <1216>, and disintegration ≤ 15 min by USP <701>. Aqueous wet granulation is possible only if the terminal drying time is kept below 90 min; prolonged heat exposure above 70°C darkens the extract and may reduce the chromatographic marker area by more than 5.0% relative to the unprocessed API.

For parenteral conversion, the aqueous fraction of the API must be separated from insoluble particulates before membrane filtration; the use of the whole powder in an injectable is not permitted without prior solubility fractionation and bioburden reduction. The solution is prepared in Water for Injection at 20–25°C under a nitrogen overlay to limit oxidative radical formation. Clarification proceeds through a 0.45 µm polyethersulfone membrane followed by a 0.22 µm sterilizing-grade polyethersulfone membrane; if filter compatibility screening shows adsorptive loss of the marker compound above 5.0%, a cellulose acetate or polyvinylidene fluoride membrane is trialled under constant pressure of 0.5–1.0 bar. The finished solution is adjusted to pH 4.5–6.5 with citrate/phosphate buffer, and sodium metabisulfite at 0.05–0.10% w/v may be added solely where forced-degradation data confirm oxidative degradation. Terminal sterilization at 121°C for 15 min is preferred, but this botanical fraction is generally heat-labile; therefore, aseptic processing with Grade A/B fill, EU GMP Annex 1 environmental monitoring, and sterile filter integrity testing before and after filtration are mandatory. Release testing includes sterility by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14 with a finished-product limit calculated from the maximum daily dose, particulate matter by USP <788> at ≤ 6000 particles ≥ 10 µm and ≤ 600 particles ≥ 25 µm per container for small-volume parenterals, and pH stability over 24 h. Amber Type II glass vials with nitrogen headspace and chlorobutyl rubber stoppers are used; if the API contains residual phenolic hydroxyl groups, contact with silicone tubing during filling should be limited because adsorption to silicone surfaces can reduce assay by 2.0–4.0%.

Capsule Filling Segregation Thresholds for Spray-Dried Botanical Powders with High Amorphous Content

Low-shear auger filling of hard capsules shifts the blend requirement from compressibility to flow and segregation resistance. The API is pre-blended with microcrystalline cellulose 102 at 30–50% w/w, lactose monohydrate 200M at 30–45% w/w, sodium starch glycolate at 2.0–4.0% w/w, colloidal silicon dioxide at 0.2–0.5% w/w, and magnesium stearate at 0.5–1.0% w/w; the final blend should show angle of repose ≤ 35°, Carr index ≤ 25.0, and loss on drying ≤ 4.0% before filling. Environmental controls are tighter than for tableting because gelatin shells exchange moisture with the room; hard gelatin capsule shells are maintained at 13–16% moisture and embrittle below 20% relative humidity, while hydroxypropyl methylcellulose shells tolerate lower equilibrium moisture but often require slower machine speeds due to static charge. Fill weight variation is controlled to ≤ ± 3.0% for target fill mass of 200–400 mg, but assay-based content uniformity by USP <905> is the release criterion, with acceptance value ≤ 15.0. Disintegration by USP <701> must be ≤ 30 min without the use of enteric coatings; if delayed release is intended for ruminant protection, a separate acid-resistant capsule or coating process is required. Capsules are packed in high-density polyethylene bottles with desiccant canisters and induction-sealed caps; moisture vapor transmission rate of the container closure should be ≤ 0.5 g/m²/day at 38°C and 90% relative humidity.

In drinking water systems, oral powders must hydrate without forming a gel layer, because the botanical fraction can swell upon contact with water and block nipples or drinking lines. The API is diluted with water-soluble carriers such as anhydrous glucose monohydrate, sucrose, or maltodextrin at 1:10 to 1:25 w/w, and the mixture is passed through a 0.250 mm sieve to break soft agglomerates. If the reconstituted drinking solution is to remain physically stable for 24 h, a suspending agent such as xanthan gum at 0.05–0.10% w/v may be added, but only after the solution is screened for viscosity below 15 mPa·s at 20°C because higher viscosity reduces voluntary water intake in swine. The powder fill mass is verified by Ph. Eur. 2.9.5; for sachet fill weights between 500 mg and 1.0 g, individual deviations should remain within ± 5.0%. Microbial limits for non-sterile oral powders follow Ph. Eur. 5.1.4, requiring total aerobic microbial count ≤ 1000 CFU/g, total yeast and mould count ≤ 100 CFU/g, and absence of Escherichia coli in 1 g. Packaging must be moisture-proof aluminium composite foil with a moisture vapor transmission rate ≤ 0.5 g/m²/day at 38°C and 90% relative humidity; pre-drying at relative humidity above 60% is mandatory because botanical powders can gain 2.0–3.0% moisture in 4 h of open-room exposure.

If the Granules Must Withstand Pneumatic Transfer Without Generating Fines Above 15%

Where wet granulation is selected for oral top-dressing or reconstitution, the resulting granules have a defined particle size and lower dust, but the granule strength must be balanced against disintegration. A high-shear granulator is charged with the API and lactose or sorbitol at 70–80% of usable volume; binder solution of hydroxypropyl methylcellulose E5 at 3.0–6.0% w/w is added at 15–22% w/w of dry mass while the impeller runs at 200–400 rpm and the chopper at 1500–3000 rpm. The wet mass is extruded through a 1.0 mm screen, dried in a fluid bed at 55–65°C to loss on drying ≤ 3.0%, and graded through 0.850 mm and 0.250 mm sieves. Target granule fraction between 250 and 850 µm should be ≥ 85%, with fines below 150 µm ≤ 10% and oversized above 1000 µm ≤ 5.0%. Granule friability is measured by rotating 10 g in a 200 mm drum at 25 rpm for 10 min; the weight fraction passing 0.150 mm after this test should not exceed 2.0%. Bulk density is controlled at 0.55–0.70 g/mL for consistent volumetric dosing. A flow test through a 7 mm orifice should exceed 10 g/s. If the granules are intended for automatic feed-dosing devices, dust below 50 µm must be kept below 2.0% w/w to avoid static adhesion to load cells and dose sensors.

During medicated feed production, cross-contamination control becomes the controlling process hazard when the API is diluted into a vitamin-mineral premix, because residual active material in mixing equipment can carry over into subsequent batches and create off-target exposure. The carrier is selected from ground corn cob, calcium carbonate, or wheat middlings with particle size 0.2–0.8 mm and moisture ≤ 10.0%; oil is not added unless dust control is necessary, and even then total added oil should remain below 2.0% w/w because higher oil levels can react with botanical lipophilic fractions. The API is first pre-blended with a portion of carrier at 1:10 w/w, then introduced into a horizontal ribbon mixer at 70–80% fill and mixed for 10–15 min. Homogeneity is confirmed by assaying 10 sample points for the marker compound; the coefficient of variation should remain ≤ 5.0%. In the European Union, the resulting medicated feed is subject to Regulation (EU) 2019/4 and the veterinary medicinal product Regulation (EU) 2019/6, including carry-over limit validation; in the United States, medicated feed applications fall under 21 CFR Part 558 and need a veterinary feed directive where the target species is a food-producing animal. Batch rinse and flush sequences with ground corn cob should reduce the carry-over marker to ≤ 0.5% of the preceding batch strength. Mineral-catalyzed degradation is a known incompatibility: the premix should not be held for more than 30 days if it contains unprotected ferrous sulfate or copper sulfate at levels above 1000 mg/kg, unless an overage is justified by real-time stability data.

Account for pH-Dependent Haze and Preservative Loss in Multi-Dose Oral Solutions

For multi-dose oral solutions, pH-dependent haze and preservative depletion are the two stability failures most frequently observed on production lines. Dissolution is performed in purified water at 25–35°C under low-shear agitation; if the API does not fully dissolve, propylene glycol or glycerol is added at 10–20% v/v and the mixture is pH-adjusted with citrate buffer to 4.0–5.5. The solution is clarified through 5 µm and 1 µm depth filters and then transferred to amber polyethylene terephthalate or Type II glass bottles with closures that have low oxygen permeability. A preservative system of potassium sorbate 0.10–0.20% w/v and sodium benzoate 0.05–0.10% w/v is evaluated by Ph. Eur. 5.1.3 preservative efficacy testing, with expected log reductions of at least 3.0 for bacteria and 1.0 for fungi at 7 days; if the botanical fraction binds benzoate, sodium propyl paraben may be considered only under regulatory confirmation for the target species. Non-sterile oral liquids must meet Ph. Eur. 5.1.4 limits for oral preparations, and the finished solution should be held at 25°C for 24 h to check for precipitate before release. Viscosity should remain below 10 mPa·s at 20°C, and pH drift during 12-month storage should remain within ± 0.3 units. Strong oxidizing agents and cationic polymers should be avoided because they can precipitate polyphenol fractions and reduce the chromatographic marker recovery. Multi-dose containers must include a calibrated dosing device, and the maximum in-use period after first opening should be validated to not exceed 28 days unless supported by preservative efficacy data.